Immunomedics Inc. said that it has received Canadiangovernment approval to begin Phase III trials of ImmuRAID-CEA, its colorectal cancer imaging agent. ImmuRAID consists ofa monoclonal antibody labeled with the radioisotopetechnetium-99m. The Warren, N.J., company filed last April forU.S. marketing approval of ImmuRAID. Immunomedics stock(NASDAQ:IMMU) closed Tuesday at $14.25, down 38 cents.


Collagen Corp. said it has sold assets from its discontinuedtitanium-based dental implant business to Implant InnovationsInc. for $200,000 plus an $800,000 promissory note.

Implant of West Palm Beach, Fla., assumed certain royaltyobligations related to the business. Collagen (NASDAQ:CGEN) ofPalo Alto, Calif., agreed not to compete with Implant in themaking or sale of similar products for three years.

(c) 1997 American Health Consultants. All rights reserved.